The antimicrobial susceptibility of Mycobacterium chelonae isolated from corneal ulcer

被引:11
作者
Hu, FR
Chang, SC
Luh, KT
Hung, PT
机构
[1] NATL TAIWAN UNIV HOSP, DEPT INTERNAL MED, TAIPEI, TAIWAN
[2] NATL TAIWAN UNIV HOSP, DEPT LAB MED, TAIPEI, TAIWAN
关键词
antibiotics; in vitro susceptibility; keratitis; Mycobacterium chelonae;
D O I
10.1076/ceyr.16.10.1056.9023
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose. To determine the in vitro susceptibility of Mycobacterium chelonae isolates from corneal ulcers to various traditional and newly-developed antimicrobial agents, alone or in combination. Methods. Fifteen strains of M. chelonae isolated from corneal ulcers were collected at the National Taiwan University Hospital from 1989 to 1993. Susceptibility to antimicrobial agents was tested by the broth microdilution method to determine the minimum inhibitory concentration (MIC). The antimicrobial effects of combinations of antimicrobial agents were assessed by the checkerboard titration method to determine the fractional inhibitory concentration (FIC) index. Results. The MIC results showed that traditional antituberculous drugs had poor activity against M. chelonae. In the aminoglycoside group, tobramycin and amikacin had better activity than gentamicin. Among macrolides, clarithromycin was especially effective, with an MIC ranging from 0.125 to 1 mu g/ml. Among various beta-lactam antibiotics, imipenem was the only one to demonstrate good anti-mycobacterial activity. Of the quinolone group, ciprofloxacin was the most effective, with an MIC ranging from 0.5 to 16 mu g/ml. Combination of an aminoglycoside with imipenem, ciprofloxacin or clarithromycin all showed antagonistic effect. Conclusions. The results suggested that amikacin, clarithromycin, imipenem and ciprofloxacin had good in vitro antimicrobial activity against M. chelonae. However, no synergistic effect could be demonstrated for combinations of an aminoglycoside with other effective drugs.
引用
收藏
页码:1056 / 1060
页数:5
相关论文
共 30 条
[1]   THE NEW MACROLIDE ANTIBIOTICS - AZITHROMYCIN, CLARITHROMYCIN, DIRITHROMYCIN, AND ROXITHROMYCIN [J].
BAHAL, N ;
NAHATA, MC .
ANNALS OF PHARMACOTHERAPY, 1992, 26 (01) :46-55
[2]   INVITRO ACTIVITIES OF AZITHROMYCIN (CP-62,993), CLARITHROMYCIN (A-56268-TE-031), ERYTHROMYCIN, ROXITHROMYCIN, AND CLINDAMYCIN [J].
BARRY, AL ;
JONES, RN ;
THORNSBERRY, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (05) :752-754
[3]   ACTIVITIES OF 4 MACROLIDES, INCLUDING CLARITHROMYCIN, AGAINST MYCOBACTERIUM-FORTUITUM, MYCOBACTERIUM-CHELONAE, AND M-CHELONAE-LIKE ORGANISMS [J].
BROWN, BA ;
WALLACE, RJ ;
ONYI, GO ;
DEROSAS, V ;
WALLACE, RJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (01) :180-184
[4]   NONTUBERCULOUS MYCOBACTERIAL KERATITIS - REPORT OF 2 CASES AND REVIEW OF THE LITERATURE [J].
BULLINGTON, RH ;
LANIER, JD ;
FONT, RL .
ARCHIVES OF OPHTHALMOLOGY, 1992, 110 (04) :519-524
[5]   CONJUNCTIVAL NECROSIS AFTER ADMINISTRATION OF TOPICAL FORTIFIED AMINOGLYCOSIDES [J].
DAVISON, CR ;
TUFT, SJ ;
DART, JKG .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1991, 111 (06) :690-693
[6]   MYCOBACTERIUM-FORTUITUM KERATITIS [J].
DUGEL, PU ;
HOLLAND, GN ;
BROWN, HH ;
PETTIT, TH ;
HOFBAUER, JD ;
SIMONS, KB ;
ULLMAN, H ;
BATH, PE ;
FOOS, RY .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1988, 105 (06) :661-669
[7]  
GRASSI C, 1995, EUR RESPIR J, V8, pS714
[8]  
GROSS RH, 1995, INVEST OPHTH VIS SCI, V36, P965
[9]   COMPARISON OF TOPICAL ANTIBIOTICS FOR TREATING MYCOBACTERIUM-FORTUITUM KERATITIS IN AN ANIMAL-MODEL [J].
HELM, CJ ;
HOLLAND, GN ;
LIN, R ;
BERLIN, OGW ;
BRUCKNER, DA .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1993, 116 (06) :700-707
[10]   OFLOXACIN AND THE TREATMENT OF PULMONARY-DISEASE DUE TO MYCOBACTERIUM-FORTUITUM [J].
ICHIYAMA, S ;
TSUKAMURA, M .
CHEST, 1987, 92 (06) :1110-1112